This volatility indicators tool runs Normalized Average True Range indicator and companion studies for Bio Rad. It emphasizes volatility indicators and range-based signals while keeping volatility, risk, and performance context in view.Provide Time Period to run this model.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Normalized Average True Range is used to analyze tradable apportunities for Bio Rad Laboratories across different markets.
Bio Rad Technical Analysis Modules
Most technical analysis of Bio Rad help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Bio from various momentum indicators to cycle indicators. When you analyze Bio charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. Bio-Rad Laboratories operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 8200 people. Liquidity and trading activity can influence how quickly new information is reflected in Bio Rad's price. Lower liquidity may increase execution variability. Bio Rad has a market cap of 7.28 B, P/E of 2.9, ROE of 10.84%.
Methodology
Unless otherwise specified, financial data for Bio Rad Laboratories is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Bio (USA Stocks:BIO) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We primarily rely on public filings and market reference sources, including disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR. Data is normalized for analytical consistency across reporting formats. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Bio Rad Laboratories may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Tracking Bio Rad inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.
Understanding Bio Rad Laboratories typically begins with financial statements and long-term trend review. Ratio context helps frame profitability, efficiency, and growth trends for Bio Rad Laboratories Stock. Outlined below are key reports that provide context for Bio Rad Laboratories Stock:
Bio Rad has a market cap of 7.28 B, operating margin of 8.87%, ROE of 10.84%. Review Trending Equities for broader portfolio context. This reflects a position in Bio Rad Laboratories within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Analysis related to Bio Rad should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Quarterly Earnings Growth
-0.83
Earnings Share
28.07
Revenue Per Share
94.689
Quarterly Revenue Growth
0.039
Return On Assets
0.0167
Bio Rad Laboratories market price can diverge from book value, the accounting figure shown on Bio balance sheet. Bio Rad's market capitalization is 7.28 B. A P/B ratio of 0.97 suggests Bio Rad trades near or below book value. Enterprise value stands at 7.08 B. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
It is useful to distinguish Bio Rad's value from its trading price, which are computed with different methods. For Bio Rad, key inputs include a P/E ratio of 2.9, a P/B ratio of 0.97, a profit margin of 29.42%, and ROE of 10.84%. The quoted price is simply the exchange level where supply meets demand.
Vlad Skutelnik ยท Macroaxis Contributor